Extra Condensed
Greg Mitchell, Founder & CEO of Font Shield, is a Type Director with over forty years of experience. To say Mitchell knows his way around the font industry would be an understatement. His mission at Font Shield is to support agencies and brands in the compliance and procurement of the fonts they license so they…
Latest
Community Generated Content - Extensis
A License to Font with Greg Mitchell
Intellectual property is something all brands recognize. And that protection extends to the typography. Fonts are integral to a brand and fall under the same copyright jurisdictions as photography, illustrations, music, and software. Therefore, creators must ensure the fonts they use are under a proper EULA (end-user license agreement.) Greg Mitchell, Founder & CEO of…
Community Generated Content - Extensis
3,285,000 Helveticas
With many options for the same font, Connect Font takes the guesswork out of font management. The correct font will be activated.
Community Generated Content - Extensis
No Font Conflicts
Discussion about what is liked about Connect Fonts and how it works seamlessly with workflow to never have font issues.
Community Generated Content - Extensis
Invite new users create and assign libraries
Welcome to Connect Fonts! When you invite new users to Connect Fonts and assign libraries to them, they can easily browse, search, and pair the fonts you’ve shared on any device. Collaboration and delivering results has become much easier. Here’s a brief guide on adding users and assigning libraries: Adding Users: 1. Log in to…
Community Generated Content - Extensis
Fiji St. Louis Interview
Ashley, the social media manager for Extensis, interviews Fitgi Saint-Louis, a creative graphic designer, typography expert, and educator. They discuss various topics such as Fiji’s preferred location for a conversation, her sources of inspiration, the role of graphic design and typography in linking language and culture, her design process, the importance of research, the impact…
Community Generated Content - Extensis
Extensis Success Center
Welcome to success center located within the Connect platform. This tool is designed to help you get the most out of your Connect software investment. With the success center, you will have access to all the resources you need to be successful. You are able to see detailed font activation data from your team that…
Latest
Analyzing the Suppressive TME in In Vitro Based Assays
In the rapidly advancing field of cancer immunotherapy, accurately modeling the tumor microenvironment (TME) has become essential to improving the predictive power of preclinical drug testing. As immune-modulating therapies surge forward, with over 4,000 immune modulators in development globally, scientists are refining assay technologies that maintain the complexity of patient-specific tumor biology. In vitro platforms…
Targeting T Cells Within the Cancer Immunity Cycle
As cancer immunotherapy continues to reshape treatment landscapes, fine-tuning T-cell responses has become a critical frontier. Recent advances in 3D organoid models and high-content imaging are enabling scientists to closely mimic patient-specific tumor environments—unlocking insights into how T cells behave, respond, and falter under immune checkpoint blockade. With over 4,000 immune modulators in clinical…
Advanced In Vitro Technologies to Investigate Therapeutic Impact on the Cancer Immunity Cycle
As immunotherapy revolutionizes cancer treatment, the need for physiologically relevant preclinical models becomes more urgent than ever. Despite the success of immune checkpoint inhibitors, a large majority of patients fail to achieve long-lasting responses, prompting researchers to explore more complex and predictive assays. The cancer immunity cycle, first described in 2013, remains a central framework…
Inside Oncology Drug Development: Overcoming Resistance with Science
In the last two decades, oncology has undergone a transformation with over 300 new cancer therapies approved by the FDA—many offering novel mechanisms of action. Despite these innovations, resistance to treatment remains a critical challenge, with cancer cells evolving or adapting to evade even the most advanced therapeutics. This issue is particularly pressing given that…